Identification and validation of genetic risk signatures associated with ME/CFS for precision drug repositioning and diagnostic triaging

PrecisionLife is a precision medicine company, driving precision medicine in complex chronic diseases.

The company is unique in its ability to understand the causal biology of complex diseases and link chronic disease patients to effective treatments via the molecular mechanism of their disease and response to treatments.

This research project forms part of PrecisionLife’s wider LOCOME (LOng COvid and Myalgic Encephalomyelitis diagnostics and stratification) Innovate UK grant, in collaboration with the University of Edinburgh and Action for ME.

The research seeks to:

• Validate and extend the company’s precision medicine analysis done to date with UK Biobank data

• Investigate disease risk and protective signatures for ME/CFS, to help develop new diagnostics and genotypic triaging tools and identify genetic risk factors, with the goal of being able to rapidly and accurately assess patients presenting with potential ME/CFS

• Help identify precision medicines in the form of novel drug treatments and repositioning opportunities targeted at specific patient subgroups within the population